CephalalgiaPub Date : 2024-08-01DOI: 10.1177/03331024241274343
Zaza Katsarava, Dawn C Buse, Elizabeth Leroux, Michel Lanteri-Minet, Fumihiko Sakai, Manjit S Matharu, Aubrey Manack Adams, Karen Carr, Kristina M Fanning, Richard B Lipton
{"title":"Disability in migraine: Multicountry results from the Chronic Migraine Epidemiology and Outcomes - International (CaMEO-I) Study.","authors":"Zaza Katsarava, Dawn C Buse, Elizabeth Leroux, Michel Lanteri-Minet, Fumihiko Sakai, Manjit S Matharu, Aubrey Manack Adams, Karen Carr, Kristina M Fanning, Richard B Lipton","doi":"10.1177/03331024241274343","DOIUrl":"10.1177/03331024241274343","url":null,"abstract":"<p><strong>Background: </strong>Few studies of migraine have evaluated migraine disability across multiple countries using the same methodology.</p><p><strong>Methods: </strong>This cross-sectional, web-based survey was conducted in 2021-2022 in Canada, France, Germany, Japan, UK and USA. Respondents with migraine were identified based on modified International Classification of Headache Disorders, 3rd edition, criteria. Headache features (Migraine Symptom Severity Score (MSSS, range: 0-21), presence of allodynia (Allodynia Symptom Checklist, ASC-12)) and migraine burden (Patient Health Questionnaire-4 (PHQ-4), Migraine-Specific Quality of Life questionnaire version 2.1 (MSQ v2.1), Work Productivity and Activity Impairment (WPAI) questionnaire) were evaluated.</p><p><strong>Results: </strong>Among 14,492 respondents with migraine across countries, the mean ± SD MSSS was 15.4 ± 3.2 and 48.5% (7026/14,492) of respondents had allodynia based on ASC-12. Of all respondents living with migraine, 35.5% (5146/14,492) reported moderate to severe anxiety and/or depression symptoms. Mean ± SD MSQ v2.1 Role Function-Restrictive, Role Function-Preventive and Emotional Function domain scores were 60.7 ± 22.9, 71.5 ± 23.0 and 65.1 ± 27.2, respectively. The WPAI mean ± SD percentages of respondents who missed work or worked impaired as a result of migraine were 6.8 ± 18.1% and 41.0 ± 30.1%, respectively.</p><p><strong>Conclusions: </strong>For every country surveyed, migraine was associated with high levels of symptom severity, with allodynia and with substantial burden.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"44 8","pages":"3331024241274343"},"PeriodicalIF":5.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142035418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CephalalgiaPub Date : 2024-08-01DOI: 10.1177/03331024241259456
Kathleen Mullin, Robert Croop, Linda Mosher, Terence Fullerton, Jennifer Madonia, Richard B Lipton
{"title":"Long-term safety of zavegepant nasal spray for the acute treatment of migraine: A phase 2/3 open-label study.","authors":"Kathleen Mullin, Robert Croop, Linda Mosher, Terence Fullerton, Jennifer Madonia, Richard B Lipton","doi":"10.1177/03331024241259456","DOIUrl":"10.1177/03331024241259456","url":null,"abstract":"<p><strong>Background: </strong>Zavegepant is the first small molecule calcitonin gene-related peptide receptor antagonist for intranasal administration for the acute treatment of migraine. The objective of this study was to evaluate the safety and tolerability of zavegepant in the acute treatment of migraine under repeated, as-needed dosing for up to one year.</p><p><strong>Methods: </strong>This phase 2/3, one-year open-label safety study of zavegepant 10 mg nasal spray for the acute treatment of migraine enrolled adults aged ≥18 years with a history of two to eight moderate to severe monthly migraine attacks. Participants used one dose of zavegepant as needed to self-treat migraine attacks of any severity, up to eight times per month, for 52 weeks.</p><p><strong>Results: </strong>Participants were enrolled between 29 June and 4 December 2020. Of the 608 participants entering long-term treatment, 603 were treated with study drug. Participants administered a mean (SD) of 3.1 (1.55) zavegepant doses per month. There were no deaths. Of the seven serious adverse events reported, none was considered related to treatment. Altogether, 6.8% (41/603) of treated participants had an adverse event leading to study drug discontinuation. The most frequent adverse event leading to discontinuation was dysgeusia (1.5% [9/603]). The most common treatment-emergent adverse events (≥5% of participants) were dysgeusia (39.1% [236/603]); nasal discomfort (10.3% [62/603]); COVID-19 (7.5% [45/603]); nausea (6.1% [37/603]); nasal congestion and throat irritation (5.5% [33/603] each); and back pain (5.3% [32/603]). Aminotransferases >3x the upper limit of normal occurred in 2.6% [16/603] of participants; none had concurrent elevations in bilirubin >2x upper limit of normal.</p><p><strong>Conclusions: </strong>One year of zavegepant 10 mg nasal spray up to eight times per month was safe and well tolerated.<b>Trial registration:</b> Clinicaltrials.gov: NCT04408794.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"44 8","pages":"3331024241259456"},"PeriodicalIF":5.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142104843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CephalalgiaPub Date : 2024-08-01DOI: 10.1177/03331024241268058
Thien Phu Do
{"title":"Clarification on the incidence and sex-specificity of sexual dysfunction as an adverse event of CGRP-targeting medications.","authors":"Thien Phu Do","doi":"10.1177/03331024241268058","DOIUrl":"10.1177/03331024241268058","url":null,"abstract":"","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"44 8","pages":"3331024241268058"},"PeriodicalIF":5.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141878456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Artificial intelligence and headache.","authors":"Anker Stubberud, Helge Langseth, Parashkev Nachev, Manjit S Matharu, Erling Tronvik","doi":"10.1177/03331024241268290","DOIUrl":"https://doi.org/10.1177/03331024241268290","url":null,"abstract":"<p><strong>Background and methods: </strong>In this narrative review, we introduce key artificial intelligence (AI) and machine learning (ML) concepts, aimed at headache clinicians and researchers. Thereafter, we thoroughly review the use of AI in headache, based on a comprehensive literature search across PubMed, Embase and IEEExplore. Finally, we discuss limitations, as well as ethical and political perspectives.</p><p><strong>Results: </strong>We identified six main research topics. First, natural language processing can be used to effectively extract and systematize unstructured headache research data, such as from electronic health records. Second, the most common application of ML is for classification of headache disorders, typically based on clinical record data, or neuroimaging data, with accuracies ranging from around 60% to well over 90%. Third, ML is used for prediction of headache disease trajectories. Fourth, ML shows promise in forecasting of headaches using self-reported data such as triggers and premonitory symptoms, data from wearable sensors and external data. Fifth and sixth, ML can be used for prediction of treatment responses and inference of treatment effects, respectively, aiming to optimize and individualize headache management.</p><p><strong>Conclusions: </strong>The potential uses of AI and ML in headache are broad, but, at present, many studies suffer from poor reporting and lack out-of-sample evaluation, and most models are not validated in a clinical setting.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"44 8","pages":"3331024241268290"},"PeriodicalIF":5.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CephalalgiaPub Date : 2024-08-01DOI: 10.1177/03331024241268212
Anker Stubberud, Solveig Borkenhagen, Francisco Oteiza, Aud Nome Dueland, Christoffer Bugge, Erik Magnus Sæther, Erling Tronvik, Lars Jacob Stovner, Marte-Helene Bjørk
{"title":"Patterns of migraine medication use in Norway: A nationwide registry-based observational study.","authors":"Anker Stubberud, Solveig Borkenhagen, Francisco Oteiza, Aud Nome Dueland, Christoffer Bugge, Erik Magnus Sæther, Erling Tronvik, Lars Jacob Stovner, Marte-Helene Bjørk","doi":"10.1177/03331024241268212","DOIUrl":"https://doi.org/10.1177/03331024241268212","url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study was to describe and discuss patterns of migraine medication use in the entire Norwegian population.</p><p><strong>Methods: </strong>In this nationwide, observational study, all individuals with a migraine-related prescription between 2010 and 2020 were identified using the Norwegian Prescription Database. The outcomes of interest were the incidence and 1-year prevalence of migraine medication users, as well as individuals with triptan overuse. Patterns of medication use were statistically compared between women and men adjusted for age, year of treatment start, comorbidities and county of residence calculating adjusted odds ratios (aOR) with 95% confidence intervals (CI).</p><p><strong>Results: </strong>We identified 327,904 migraine medication users. The incidence ranged from 0.39% to 0.46%, and the 1-year prevalence increased from 1.99% to 2.99%. Preventive use increased >50% during the study period. Preventives were significantly more often prescribed to women than to men (39.72% vs. 33.75%; aOR 1.41, 95% CI 1.38 to 1.44). Triptan overuse was significantly more common among women, but women with overuse were more often using preventives, as compared to men (56.64% vs 52.69%; aOR = 1.43, 95% CI 1.37 to 1.49).</p><p><strong>Conclusion: </strong>The prevalence of medically treated migraine is low. Overuse of triptans is frequent, especially among women. Clinicians should be encouraged to try out different triptans, recognize triptan overuse, and prescribe preventives when indicated.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"44 8","pages":"3331024241268212"},"PeriodicalIF":5.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141987527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CephalalgiaPub Date : 2024-08-01DOI: 10.1177/03331024241274366
Andreas Vinther Thomsen, Mohammad Al-Mahdi Al-Karagholi, Anders Hougaard, Sisse Rye Ostrowski, Messoud Ashina
{"title":"Effects of levcromakalim in patients with migraine aura without headache: An experimental study.","authors":"Andreas Vinther Thomsen, Mohammad Al-Mahdi Al-Karagholi, Anders Hougaard, Sisse Rye Ostrowski, Messoud Ashina","doi":"10.1177/03331024241274366","DOIUrl":"https://doi.org/10.1177/03331024241274366","url":null,"abstract":"<p><strong>Background/hypothesis: </strong>Levcromakalim has previously been shown to induce attacks of migraine with aura in certain individuals. In this study, we tested the migraine-inducing effect of levcromakalim in a cohort of participants with migraine aura without headache.</p><p><strong>Methods: </strong>In a double-blind, randomized, placebo-controlled cross-over study, eight adult participants with migraine with aura received intravenous infusions of levcromakalim and saline. Headache, aura and associated symptoms were evaluated for 24 h following administration of the study drug. The primary endpoint was occurrence of migraine-like attacks with or without aura in the 24-h observation period.</p><p><strong>Results: </strong>Five participants (62.5%) developed migraine of any type following levcromakalim compared with three participants (37.5%) following placebo. No participants developed aura following levcromakalim.</p><p><strong>Conclusion/interpretation: </strong>Our findings suggest that the aura-inducing effect of levcromakalim is likely not based on direct induction of cortical spreading depression but may involve activation of the trigeminovascular system. This hypothesis should be further explored in future studies.</p><p><strong>Clinicaltrials.gov identifier: </strong>NCT04905654.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"44 8","pages":"3331024241274366"},"PeriodicalIF":5.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142003727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CephalalgiaPub Date : 2024-08-01DOI: 10.1177/03331024241274266
Haidar M Al-Khazali, Zainab Al-Sayegh, Samaira Younis, Rune H Christensen, Messoud Ashina, Henrik W Schytz, Sait Ashina
{"title":"Systematic review and meta-analysis of Neck Disability Index and Numeric Pain Rating Scale in patients with migraine and tension-type headache.","authors":"Haidar M Al-Khazali, Zainab Al-Sayegh, Samaira Younis, Rune H Christensen, Messoud Ashina, Henrik W Schytz, Sait Ashina","doi":"10.1177/03331024241274266","DOIUrl":"10.1177/03331024241274266","url":null,"abstract":"<p><strong>Background: </strong>The present study aimed to assess the burden of neck pain in adults with migraine and tension-type headache (TTH), utilizing the Neck Disability Index (NDI) and Numeric Pain Rating Scale (NPRS).</p><p><strong>Methods: </strong>A systematic literature search was conducted on PubMed and Embase to identify observational studies assessing NDI and NPRS in populations with migraine or TTH. The screening of articles was independently performed by two investigators (HMA and ZA). Pooled mean estimates were calculated through random-effects meta-analysis. The <i>I</i><sup>2</sup> statistic assessed between-study heterogeneity, and meta-regression further explored heterogeneity factors.</p><p><strong>Results: </strong>Thirty-three clinic-based studies met the inclusion criteria. For participants with migraine, the pooled mean NDI score was 16.2 (95% confidence interval (CI) = 13.2-19.2, <i>I</i><sup>2 </sup>= 99%). Additionally, the mean NDI was 5.5 (95% CI = 4.11-6.8, <i>p</i> < 0.001) scores higher in participants with chronic compared to episodic migraine. The pooled mean NDI score for participants with TTH was 13.7 (95% CI = 4.9-22.4, <i>I</i><sup>2 </sup>= 99%). In addition, the meta-analysis revealed a mean NPRS score of 5.7 (95% CI = 5.1-6.2, <i>I</i><sup>2</sup> = 95%) across all participants with migraine.</p><p><strong>Conclusions: </strong>This systematic review and meta-analysis shows a greater degree of neck pain-related disability in migraine compared to TTH. Nevertheless, the generalizability of these findings is constrained by methodological variations identified in the current literature.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"44 8","pages":"3331024241274266"},"PeriodicalIF":5.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142104844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Glucocorticoid signaling mediates stress-induced migraine-like behaviors in a preclinical mouse model.","authors":"Ya-Yu Hu, Rimenez Souza, Athithyaa Muthuraman, Leela Knapp, Christa McIntyre, Gregory Dussor","doi":"10.1177/03331024241277941","DOIUrl":"10.1177/03331024241277941","url":null,"abstract":"<p><strong>Background: </strong>Stress is one of the most common precipitating factors in migraine and is identified as a trigger in nearly 70% of patients. Responses to stress include release of glucocorticoids as an adaptive mechanism, but this may also contribute to migraine attacks. Here, we investigated the role of glucocorticoids on stress-induced migraine-like behaviors.</p><p><strong>Methods: </strong>We have shown previously that repeated stress in mice evokes migraine-like behavioral responses and priming to a nitric oxide donor. Metyrapone, mifepristone, and corticosterone (CORT) were used to investigate whether CORT contributes to the stress-induced effects. Facial mechanical hypersensitivity was evaluated by von Frey testing and grimace scoring assessed the presence of non-evoked pain. We also measured serum CORT levels in control, stress, and daily CORT injected groups of both male and female mice.</p><p><strong>Results: </strong>Metyrapone blocked stress-induced responses and priming in male and female mice. However, repeated CORT injections in the absence of stress only led to migraine-like behaviors in females. Both female and male mice showed similar patterns of serum CORT in response to stress or exogenous administration. Finally, administration of mifepristone, the glucocorticoid receptor antagonist, prior to each stress session blocked stress-induced behavioral responses in male and female mice.</p><p><strong>Conclusions: </strong>These findings demonstrate that while CORT synthesis and receptor activation is necessary for the behavioral responses triggered by repeated stress, it is only sufficient in females. Better understanding of how glucocorticoids contribute to migraine may lead to new therapeutic opportunities.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"44 8","pages":"3331024241277941"},"PeriodicalIF":5.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11578425/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142104842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CephalalgiaPub Date : 2024-08-01DOI: 10.1177/03331024241266980
Igor Petrušić, Paolo Martelletti
{"title":"Comment on \"What predicts citation counts and translational impact in headache research? A machine learning analysis\".","authors":"Igor Petrušić, Paolo Martelletti","doi":"10.1177/03331024241266980","DOIUrl":"https://doi.org/10.1177/03331024241266980","url":null,"abstract":"","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"44 8","pages":"3331024241266980"},"PeriodicalIF":5.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141878457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CephalalgiaPub Date : 2024-08-01DOI: 10.1177/03331024241271976
Johanne Gry Larsen, Mikkel Johannes Henningsen, William Kristian Karlsson, Rune Häckert Christensen, Haidar Muhsen Al-Khazali, Faisal Mohammad Amin, Håkan Ashina
{"title":"Epidemiology and clinical features of short-lasting unilateral neuralgiform headache attacks: A systematic review and meta-analysis.","authors":"Johanne Gry Larsen, Mikkel Johannes Henningsen, William Kristian Karlsson, Rune Häckert Christensen, Haidar Muhsen Al-Khazali, Faisal Mohammad Amin, Håkan Ashina","doi":"10.1177/03331024241271976","DOIUrl":"10.1177/03331024241271976","url":null,"abstract":"<p><strong>Background: </strong>To synthesize the available epidemiologic data on short-lasting unilateral neuralgiform headache attacks (SUNHA). This, in turn, might inform diagnostic work-up and clinical decision-making.</p><p><strong>Methods: </strong>EMBASE and PubMed were searched for observational studies reporting on the prevalence or relative frequency of SUNHA or its individual clinical features. Two investigators independently conducted title and abstract screening, full-text review, data extraction, and risk of bias assessment, and random-effects meta-analyses were performed to estimate the prevalence or relative frequency of SUNHA and its individual clinical features.</p><p><strong>Results: </strong>Fifteen clinic-based studies met our eligibility criteria. Of these, five studies reported estimates on the relative frequency of SUNHA among adults evaluated for headache or facial pain, yielding a pooled relative frequency as 0.32% (95% confidence interval = 0.17-0.62; <i>I</i><sup>2</sup><i><sup> </sup></i>= 89.9%). Most often, SUNHA presented as episodic, side-locked stabbing headache of severe pain intensity, predominantly affecting the ophthalmic and/or maxillary branch of the trigeminal nerve. The most common cranial autonomic features were lacrimation, conjunctival injection, rhinorrhea and nasal congestion.</p><p><strong>Conclusions: </strong>SUNHA is a rare headache disorder with distinct clinical features. However, our findings must be interpreted with caution as a result of between-study heterogeneity and lack of population-based studies, underscoring the need for further epidemiologic research.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"44 8","pages":"3331024241271976"},"PeriodicalIF":5.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142003728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}